In June, the American Society of Anesthesiologists reported anecdotal evidence of GLP-1s resulting in regurgitation and aspiration in surgeries. The drugs delay gastric emptying, meaning normal fasting rules weren’t enough for normal preoperative strategies, so the ASA recommended patients miss a dose. The American Association of Nurse Anesthesiology published a similar guidance in March.
Other experts acknowledged seeing similar anecdotal evidence but said the guidelines were an overreaction and created more issues. The American Gastroenterological Association called the issue a “clinical dilemma,” adding that too many surgeries were canceled due to a perceived risk.
In a study published April 22 in JAMA, Stanford Medicine researchers evaluated more than 23,000 patient records to investigate the surgical risks associated with GLP-1 use.
They found none.
“Overall incidence of postoperative respiratory complications was 3.5% for those with a GLP-1 RA fill and 4% for those without,” they wrote. “Results of this study suggest that liberalizing the withholding guidelines for GLP-1 RAs preoperatively should be considered.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
